Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.475    -0.025 (-5.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £2.15m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Update: Joint services alliance w. Jubilant Biosys

8 Mar 2011 07:00

RNS Number : 4572C
Physiomics PLC
08 March 2011
 



Physiomics plc

 

(the "Company")

 

Update: Joint services alliance with Jubilant Biosys

 

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is continuing to progress its Joint Services Alliance with Jubilant Biosys Limited ("Jublilant").

Further to the announcement of 22 September 2010, Physiomics can confirm that the experimental phase of the collaboration has been completed. The Company and Jubilant have now agreed to commence commercial discussions and sign a legally binding Alliance Agreement.

A further announcement will be made if an agreement is executed.

Physiomics can also confirm that the Company's interim statement will be released in the next few days.

 

Physiomics plc

Dr Mark Chadwick, CEO 

+44 (0)1865 784985

 

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURLLFVFVTIDIIL
Date   Source Headline
27th May 20207:00 amRNSFundraise
15th May 20201:00 pmRNSHolding(s) in Company
28th Apr 20202:50 pmRNSConference attendance and presentation
16th Apr 20207:00 amRNSConfirmation of Twitter account
9th Apr 202012:28 pmRNSHolding(s) in Company
6th Apr 20207:00 amRNSAwarded further Bicycle Therapeutics contract
19th Mar 20207:00 amRNSCOVID-19 update
10th Mar 20207:00 amRNSNIHR i4i award
5th Mar 20207:00 amRNSPhysiomics awarded further contract by Merck
3rd Mar 20207:00 amRNSAwarded two further contracts by Bicycle
27th Dec 20193:45 pmRNSHolding(s) in Company
23rd Dec 20197:00 amRNSContract award
20th Dec 201910:30 amRNSMerck Contracts
19th Nov 201912:52 pmRNSResult of AGM
21st Oct 20197:00 amRNSDispatch of Annual Report and Notice of AGM
30th Sep 20197:00 amRNSFinal Results for the Year Ended 30 June 2019
5th Aug 20197:00 amRNSDirector Dealing
30th Jul 20197:00 amRNSTrading Update
22nd Jul 20199:03 amRNSHolding(s) in Company
8th Jul 20197:00 amRNSAgreement with Bicycle and Cancer Research UK
2nd Jul 20191:30 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSContract Award
31st May 20197:00 amRNSChange of Adviser
14th May 20197:00 amRNSInnovate UK Award Project
3rd May 201912:00 pmRNSPhysiomics participates at NIHR event
30th Apr 20192:00 pmRNSConference attendance and presentation
27th Mar 20191:00 pmRNSIssue of Options
26th Mar 20191:00 pmRNSAIM Rule 26 Website Change
20th Mar 20197:00 amRNSConference Attendance and Presentation
21st Feb 20197:00 amRNSInterim Results
7th Jan 20197:00 amRNSConference Attendance
3rd Jan 20197:00 amRNSStrategic Collaboration
17th Dec 20187:00 amRNSRenewal of Agreement with Merck
20th Nov 201812:56 pmRNSResult of AGM
15th Oct 20181:00 pmRNSDispatch of Annual Report and Shareholder Circular
8th Oct 20187:00 amRNSFinal Results for the Year Ended 30 June 2018
9th Aug 20187:00 amRNSContract award
2nd Jul 20181:57 pmRNSPhysiomics Expands Technical Team
21st Jun 20187:00 amRNSTrading Update
11th Jun 20184:05 pmRNSUpdated Website
23rd May 20187:00 amRNSPlacing
26th Apr 201811:06 amRNSContract Award
6th Apr 20182:40 pmRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSPhysiomics to Present at AACR Annual Meeting
27th Mar 20185:23 pmRNSIssue of Options
14th Mar 20187:00 amRNSAward of New Innovate UK Grant
12th Mar 20187:00 amRNSCompletion of Innovate UK Grant Project
19th Feb 20187:00 amRNSInterim Results Statement
9th Feb 20187:00 amRNSContract Award
26th Jan 20187:00 amRNSNew Major Pharmaceutical Client

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.